#153995

Anti-VLDL [5F3]

Cat. #153995

Anti-VLDL [5F3]

Cat. #: 153995

Sub-type: Primary antibody

Unit size: 100 ug

Target: Very low density lipoprotein receptor

Class: Monoclonal

Application: WB ; ELISA

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: University of Maryland

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-VLDL [5F3]
  • Alternate name: VLDL receptor
  • Research fields: Cell signaling and signal transduction;Genetics;Neurobiology
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Purpose: Marker
  • Conjugation: Unconjugated
  • Molecular weight: 96 kDa
  • Reactivity: Human
  • Host: Mouse
  • Application: WB ; ELISA
  • Description: The LDLR family is composed of several cell-surface proteins including VLDL. This receptor has been shown to interact with apoE, a process that is inhibited by RAP. Like LRP, VLDL is expressed within the brain with mutations in the protein leading to neurological disorders.
  • Immunogen: recombinant sVLDLr1-8
  • Isotype: IgG1

Target Details

  • Target: Very low density lipoprotein receptor
  • Molecular weight: 96 kDa
  • Tissue cell line specificity: Mouse
  • Target background: The LDLR family is composed of several cell-surface proteins including VLDL. This receptor has been shown to interact with apoE, a process that is inhibited by RAP. Like LRP, VLDL is expressed within the brain with mutations in the protein leading to neurological disorders.

Applications

  • Application: WB ; ELISA

Handling

  • Format: Liquid
  • Unit size: 100 ug
  • Shipping conditions: Shipping at 4° C

References

  • Ruiz et al. 2005. J Lipid Res. 46(8):1721-31. PMID: 15863833.
  • The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor.